You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 129 No. 2, February 1994 TABLE OF CONTENTS
  Archives
  •  Online Features
  Original Articles
 This Article
 •References
 •Full text PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

A Phase II Study to Evaluate Recombinant Platelet-Derived Growth Factor-BB in the Treatment of Stage 3 and 4 Pressure Ulcers

Thomas A. Mustoe, MD; Neal R. Cutler, MD; Richard M. Allman, MD; Patricia S. Goode, MD; Thomas F. Deuel, MD; Jo Ann Prause, PhD; Moraye Bear, MS, MA; Cuneyt M. Serdar, PhD; Glenn F. Pierce, PhD, MD

Arch Surg. 1994;129(2):213-219.


Abstract

Objective
To determine the efficacy of the daily topical application of recombinant platelet-derived growth factor—BB (rPDGF-BB), a recognized vulnerary agent, in the treatment of deep pressure ulcers.

Design
Prospective, randomized, double-blind trial.

Setting
Patients were treated in a nursing home or a hospital setting before transfer to a nursing home.

Patients
Eligibility criteria included a clean pressure ulcer that had been adequately débrided and the absence of severe cardiac, pulmonary, or renal conditions. The causes of the ulcers were not related to a venous or arterial vascular disorder. The patients were elderly (mean age, 68 to 74 years).

Interventions
After randomization, patients were given daily topical aqueous rPDGF-BB (dosage, 100 or 300 µg/mL) or placebo and saline gauze dressings were applied daily in addition to frequent turning.

Main Outcome Measure
Serial volume measurements of the healing wounds were taken using alginate molds.

Results
The ulcers of 41 patients were analyzed. At the end of 28 days, median ulcer volumes had decreased to 83%, 29%, and 40% of the initial size in the groups receiving placebo, rPDGF-BB, 100 µg/dL, and rPDGF-BB, 300 µg/mL, respectively. When adjusted for initial volume, ulcer volume after 28 days of treatment was smaller in the rPDGF-BB—treated groups compared with the placebo group (analysis of covariance, P=.056). Ulcers in the two rPDGF-BB—treated groups were significantly smaller in volume compared with those in the placebo group, using a linear contrast procedure.

Conclusions
Data from this small trial suggest that local application of rPDGF-BB may be of therapeutic benefit in accelerating the healing of chronic pressure ulcers.

(Arch Surg. 1994;129:213-219)



Author Affiliations

From the Division of Plastic and Reconstructive Surgery, Northwestern Medical School, Chicago, Ill (Dr Mustoe); California Clinical Trials, Beverly Hills (Dr Cutler); the Center for Aging and Division of Gerontology and Geriatric Medicine, Department of Veterans Affairs Medical Center, University of Alabama at Birmingham (Drs Allman and Goode); Division of Hematology, the Departments of Medicine, Biochemistry, and Molecular Biophysics, The Jewish Hospital, Washington University School of Medicine, St Louis, Mo (Dr Deuel); and the Departments of Biometrics (Drs Prause and Bear), Product Development (Dr Serdar), and Experimental Pathology (Dr Pierce), Amgen Inc, Thousand Oaks, Calif.



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Treatment of Pressure Ulcers: A Systematic Review
Reddy et al.
JAMA 2008;300:2647-2662.
ABSTRACT | FULL TEXT  

Wound-induced ATP release and EGF receptor activation in epithelial cells
Yin et al.
J. Cell Sci. 2007;120:815-825.
ABSTRACT | FULL TEXT  

The Promise of Topical Growth Factors in Healing Pressure Ulcers
Thomas
ANN INTERN MED 2003;139:694-695.
FULL TEXT  

Issues and Dilemmas in the Prevention and Treatment of Pressure Ulcers: A Review
Thomas
J Gerontol A Biol Sci Med Sci 2001;56:M328-M340.
ABSTRACT | FULL TEXT  

Enhancement of Wound Healing by Hyperbaric Oxygen and Transforming Growth Factor {beta}3 in a New Chronic Wound Model in Aged Rabbits
Bonomo et al.
Arch Surg 2000;135:1148-1153.
ABSTRACT | FULL TEXT  

Recent Advances in Wound Healing
Bello and Phillips
JAMA 2000;283:716-718.
FULL TEXT  

The Effect of New Technologies on Plastic Surgery
Mustoe and Han
Arch Surg 1999;134:1178-1183.
ABSTRACT | FULL TEXT  

Acceleration of Wound Healing With Topically Applied Deoxyribonucleosides
Chen et al.
Arch Surg 1999;134:520-525.
ABSTRACT | FULL TEXT  

Transforming Growth Factor-ß1 Fails to Stimulate Wound Healing and Impairs Its Signal Transduction in an Aged Ischemic Ulcer Model : Importance of Oxygen and Age
Wu et al.
Am. J. Pathol. 1999;154:301-309.
ABSTRACT | FULL TEXT  

The Effects of Platelet-Derived Growth Factor-BB on Healing of the Rabbit Medial Collateral Ligament: An In Vivo Study
Hildebrand et al.
Am J Sports Med 1998;26:549-554.
ABSTRACT | FULL TEXT  

Plastic Surgery
Zook
JAMA 1994;271:1703-1704.
ABSTRACT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1994 American Medical Association. All Rights Reserved.